JP2025508317A5 - - Google Patents
Info
- Publication number
- JP2025508317A5 JP2025508317A5 JP2024543273A JP2024543273A JP2025508317A5 JP 2025508317 A5 JP2025508317 A5 JP 2025508317A5 JP 2024543273 A JP2024543273 A JP 2024543273A JP 2024543273 A JP2024543273 A JP 2024543273A JP 2025508317 A5 JP2025508317 A5 JP 2025508317A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- seq
- amino acid
- acid sequence
- bispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210068506.0 | 2022-01-20 | ||
| CN202210068506 | 2022-01-20 | ||
| PCT/CN2023/072510 WO2023138551A1 (zh) | 2022-01-20 | 2023-01-17 | 抗cd3和抗cd20双特异性抗体及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508317A JP2025508317A (ja) | 2025-03-26 |
| JP2025508317A5 true JP2025508317A5 (enExample) | 2025-05-12 |
Family
ID=87183066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024543273A Pending JP2025508317A (ja) | 2022-01-20 | 2023-01-17 | 抗ｃｄ３及び抗ｃｄ２０二重特異性抗体、並びにその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250154275A1 (enExample) |
| EP (1) | EP4467571A4 (enExample) |
| JP (1) | JP2025508317A (enExample) |
| KR (1) | KR20240137640A (enExample) |
| CN (1) | CN116462765A (enExample) |
| AU (1) | AU2023209012A1 (enExample) |
| CA (1) | CA3249231A1 (enExample) |
| WO (1) | WO2023138551A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| WO2025131077A1 (zh) * | 2023-12-21 | 2025-06-26 | 上海君实生物医药科技股份有限公司 | 抗cd3多特异性抗体及用途 |
| CN122255272A (zh) * | 2024-12-19 | 2026-06-23 | 上海橙帆医药有限公司 | 具有t细胞激活功能的抗体 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2578685T3 (pl) | 2005-08-23 | 2020-01-31 | The Trustees Of The University Of Pennsylvania | Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| ES2809455T3 (es) * | 2014-11-17 | 2021-03-04 | Regeneron Pharma | Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20 |
| CN107660214B (zh) * | 2015-01-08 | 2022-02-08 | 根马布股份公司 | 针对cd3和cd20的双特异性抗体 |
| EA039429B1 (ru) * | 2015-05-13 | 2022-01-26 | Ридженерон Фармасьютикалз, Инк. | Способы лечения опухолей с применением биспецифического антитела cd3xcd20 |
| WO2017210485A1 (en) * | 2016-06-01 | 2017-12-07 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma |
| KR102692708B1 (ko) * | 2016-12-20 | 2024-08-07 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법 |
| JP2020521791A (ja) * | 2017-06-02 | 2020-07-27 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療のためのｉｉ型抗ｃｄ２０抗体及び抗ｃｄ２０／ｃｄ３０二重特異性抗体 |
| CN108059680B (zh) * | 2017-12-26 | 2020-07-24 | 北京东方百泰生物科技有限公司 | 一种针对cd20和cd3的双特异性抗体 |
| EP3847196A4 (en) * | 2018-09-07 | 2023-01-04 | ITabMed (HK) Limited | BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF |
| BR112021008486A2 (pt) * | 2018-11-01 | 2021-10-26 | Shandong New Time Pharmaceutical Co., Ltd | Anticorpo biespecífico e seu uso |
| CN112969476B (zh) * | 2018-12-07 | 2024-06-14 | 江苏恒瑞医药股份有限公司 | 多特异性蛋白分子 |
| TWI821474B (zh) * | 2018-12-07 | 2023-11-11 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｃｄ３抗體及其藥物用途 |
| EP3917969A4 (en) * | 2019-01-28 | 2023-02-01 | Wuxi Biologics Ireland Limited | NEW BISPECIFIC CD3/CD20 POLYPEPTIDIC COMPLEXES |
| CN110551221B (zh) * | 2019-07-02 | 2021-03-05 | 广州爱思迈生物医药科技有限公司 | 一种双特异性抗体及其制备方法与应用 |
| CN115894701A (zh) * | 2021-09-30 | 2023-04-04 | 上海君实生物医药科技股份有限公司 | 结合cd3的抗体及其用途 |
-
2023
- 2023-01-17 CN CN202310071807.3A patent/CN116462765A/zh active Pending
- 2023-01-17 CA CA3249231A patent/CA3249231A1/en active Pending
- 2023-01-17 WO PCT/CN2023/072510 patent/WO2023138551A1/zh not_active Ceased
- 2023-01-17 US US18/832,031 patent/US20250154275A1/en active Pending
- 2023-01-17 JP JP2024543273A patent/JP2025508317A/ja active Pending
- 2023-01-17 KR KR1020247027768A patent/KR20240137640A/ko active Pending
- 2023-01-17 EP EP23742866.9A patent/EP4467571A4/en active Pending
- 2023-01-17 AU AU2023209012A patent/AU2023209012A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018214223B2 (en) | Low pH pharmaceutical composition comprising T cell engaging antibody constructs | |
| JP2024036342A (ja) | Ｃｄ３を標的とする抗体、二重特異性抗体及びその使用 | |
| JP7611931B2 (ja) | ガイダンス及びナビゲーションコントロール（ｇｎｃ）抗体様タンパク質、その製造方法及び使用方法 | |
| US20240392003A1 (en) | Multispecific antibodies having specificity for ror1 and cd3 | |
| JP2021524478A5 (enExample) | ||
| EP3645741A2 (en) | Anti-4-1bb antibodies and methods of making and using thereof | |
| JP2022533538A5 (enExample) | ||
| JP2022111148A (ja) | 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体 | |
| TW202334204A (zh) | 條件性活化之抗原結合多肽複合物及其使用方法 | |
| EP4155318A1 (en) | Bispecific antibody and use thereof | |
| CN113574069A (zh) | 抗pd-l1抗体及其用途 | |
| JP7592712B2 (ja) | ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法 | |
| KR20220167331A (ko) | 항-flt3 항체 및 조성물 | |
| WO2021167885A1 (en) | Cd137 binding molecules and uses thereof | |
| CN119816523A (zh) | 抗Nectin-4抗体和包含其的多特异性抗体 | |
| JP2025516590A5 (enExample) | ||
| WO2023180346A1 (en) | Deimmunized antibodies specific for cd3 | |
| EP4717714A1 (en) | Anti-pd-1-anti-vegf bispecific antibody, pharmaceutical composition thereof and use thereof | |
| CN118369340A (zh) | 一种双特异性抗原结合蛋白 | |
| TW202333788A (zh) | 一種抗ｔｎｆｒ２抗體藥物組合物 | |
| WO2025162198A1 (zh) | 双抗细胞因子融合蛋白及其用途 | |
| HK40112840A (en) | Anti-cd19 antibodies and methods of using and making thereof | |
| RU2025119828A (ru) | Связывающие белки, связывающие pd-1×4-1bb | |
| EP4676972A1 (en) | Isolated bispecific antibody that specifically binds to cd3 and tumor antigen, and use thereof | |
| CN119285769A (zh) | 多特异性抗体及其医药用途 |